Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:David_Meek
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
|
| gptkbp:foundedYear |
1995
|
| gptkbp:founder |
gptkb:Charles_M._Baum
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirati Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notable_for |
gptkb:MRTX1719
gptkb:Sitravatinib KRAS inhibitors |
| gptkbp:notableProduct |
gptkb:adagrasib
|
| gptkbp:numberOfEmployees |
~400
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:specialty |
targeted cancer therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:MRTX
|
| gptkbp:website |
https://www.mirati.com/
|
| gptkbp:bfsParent |
gptkb:adagrasib
|
| gptkbp:bfsLayer |
6
|